Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Outset Medical, Inc. (OM) Leslie Trigg on Q4 2021 Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. The Company also announced that Leslie Trigg has been appointed Chair of the Board of Directors in addition to her ongoing role as President and Chief Executive Officer. Recent Highlights

Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results

Outset Medical, Inc. (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Outset Medical, Inc. (OM) Q4 Earnings Expected to Decline

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 12:40pm PT / 3:40pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outs

Outset Medical to Present at SVB Leerink Global Healthcare Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 16, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Chief Financial Off

Outset Medical to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022

This stock has a market cap of close to $2 billion and a market opportunity of more than $11 billion per year.

Why This Under-the-Radar Healthcare Stock Could Be a Big Winner

The FDA has granted 510(k) clearance for Outset Medical Inc's (NASDAQ: OM) new sterilization method of the cartridge utilized in its Tablo Hemodialysis System, enabling full production in North America. The Tablo cartridge is a single-use disposable that works in concert with the console to deliver dialysis treatment.

Outset Medical's Tablo Hemodialysis System Cartridge Receives FDA Approval For Manufacturing In North America

The stock price of Outset Medical Inc (NASDAQ: OM) increased by over 5% after hours today. This is why it happened.

Outset Medical (OM) Stock: Why The Price Increased Today

SAN JOSE, Calif.--(BUSINESS WIRE)-- #BetterBeginsNow--Outset Medical's Tablo® Hemodialysis System cartridge receives FDA 510(k) clearance enabling production in North America.

Tablo® Hemodialysis System Cartridge Receives FDA 510(k) Clearance Enabling Production in North America

SAN JOSE, Calif.--(BUSINESS WIRE)-- #BetterBeginsNow--Outset Medical, a medical technology focused on changing the dialysis industry, has been named to Fast Company's Next Big Things in Tech list

Outset Medical Named to Fast Company's First-Ever List of the Next Big Things in Tech

The consensus price target hints at a 27.4% upside potential for Outset Medical, Inc. (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 27% Upside in Outset Medical, Inc. (OM): Here's What You Should Know

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the release of its inaugural Environmental, Social, and Governance (ESG) report highlighting its ESG-related programs, priorities, goals, and performance. “At Outset, our ESG journey is rooted in our mission to catalyze permanent and profound change in where, when, and how dialysis i

Outset Medical Launches Inaugural ESG Report

Outset Medical, Inc. (OM) Leslie Trigg on Q3 2021 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2021. Recent Highlights Recorded net revenue of $26.3 million in the third quarter of 2021, a 91.3% increase compared to $13.8 million in the third quarter of 2020 Achieved gross margin of 11.2% in the third

Outset Medical Reports Third Quarter 2021 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the Stifel 2021 Virtual Health Care Conference on Tuesday, November 16, 2021 at 1:40pm PT / 4:40pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outset website

Outset Medical to Present at Stifel 2021 Virtual Health Care Conference

SAN JOSE, Calif.--(BUSINESS WIRE)-- #BetterBeginsNow--Outset Medical announced that its Tablo® Hemodialysis System has received the first-ever approval from CMS for TPNIES.

Outset Medical's Tablo® Hemodialysis System Receives Landmark TPNIES Approval From CMS

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 3, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host

Outset Medical to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

There are several healthcare companies in Berkshire Hathaway's portfolio, but only one in its top 10 holdings.

Warren Buffett's Largest Healthcare Stock Investment

This innovative company is well off its highs and could be worth a look.

1 Beaten-Down Healthcare Stock to Put on Your Radar

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming virtual investor conferences. Outset will participate in the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 and the Morgan Stanley 19th Annual Global Healthcare Conference on

Outset Medical to Present at Upcoming September Investor Conferences

Outset Medical, Inc. (OM) Leslie Trigg on Q2 2021 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Recorded net revenue of $25.2 million in the second quarter of 2021, a 115% increase compared to $11.7 million in the second quarter of 2020 Achieved gross margin of 4.2% in the second qua

Outset Medical Reports Second Quarter 2021 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Nabeel Ahmed, currently serving as Outset's Interim Chief Financial Officer, has transitioned to the permanent role of Chief Financial Officer, effective immediately. “Nabeel's extensive experience across a variety of finance roles and his tenure as a leader at Outset give me gr

Outset Medical Names Nabeel Ahmed as Chief Financial Officer

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Interim Chief Financial Officer, will

Outset Medical to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Medical technology company Outset Medical Inc's (NASDAQ: OM) Chief Financial Officer, Rebecca Chambers, is set to resign from the position to pursue other opportunities, effective July 16, 2021. Outset has named Nabeel Ahmed, Vice President, Finance, as the interim CFO, effective after Rebecca's departure.

News for Outset Medical Stock (OM)